Breaking News Instant updates and real-time market news.

ACHC

Acadia

$26.11

0.34 (1.32%)

, ALNA

Allena Pharmaceuticals

$4.12

-0.15 (-3.51%)

04:55
09/05/19
09/05
04:55
09/05/19
04:55

Baird to hold a conference

2019 Global Healthcare Conference will be held in New York on September 4-5.

ACHC

Acadia

$26.11

0.34 (1.32%)

ALNA

Allena Pharmaceuticals

$4.12

-0.15 (-3.51%)

APLS

Apellis

$28.50

1.1 (4.01%)

ARWR

Arrowhead

$34.25

1.02 (3.07%)

BPMC

Blueprint Medicines

$75.35

1.34 (1.81%)

CERS

Cerus

$5.03

-0.24 (-4.55%)

EHC

Encompass Health

$60.25

-0.58 (-0.95%)

EIGR

Eiger BioPharmaceuticals

$10.60

-0.27 (-2.48%)

GNCA

Genocea

$3.46

0.24 (7.45%)

HARP

Harpoon Therapeutics

$14.50

0.2 (1.40%)

HNGR

Hanger

$18.69

0.05 (0.27%)

RARE

Ultragenyx

$45.00

-6.28 (-12.25%)

PODD

Insulet

$157.27

-10.29 (-6.14%)

PIRS

Pieris Pharmaceuticals

$4.99

0.15 (3.10%)

NVCR

Novocure

$84.39

-2.82 (-3.23%)

NBIX

Neurocrine

$97.70

-0.31 (-0.32%)

MYOV

Myovant Sciences

$8.20

0.07 (0.86%)

  • 05

    Sep

  • 05

    Sep

  • 05

    Sep

  • 07

    Sep

  • 09

    Sep

  • 09

    Sep

  • 09

    Sep

  • 11

    Sep

  • 12

    Sep

  • 16

    Sep

  • 19

    Sep

  • 23

    Sep

  • 23

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 13

    Nov

ACHC Acadia
$26.11

0.34 (1.32%)

04/23/19
SBSH
04/23/19
NO CHANGE
SBSH
Buy
Citi opens 'Positive Catalyst Watch' on Acadia for potential asset sale
Citi analyst Ralph Giacobbe opened a "Positive Catalyst Watch" on Acadia Healthcare following headlines suggesting the company is seeking a sale of its U.K. business, and specifically the Priory assets for $1.3B. The analyst sees "some optionality," whether it is an outright sale of Priory or select asset sales in the region. He keeps a Buy rating on the shares.
03/04/19
JEFF
03/04/19
NO CHANGE
Target $40
JEFF
Buy
Acadia guidance acheivable, possibly conservative, says Jefferies
Jefferies analyst Brian Tanquilut said the articulation from Acadia Healthcare management of the bridge from Q4 earnings to 2019 EBITDA guidance underscored the achievability, and possibly even conservatism, of the company's outlook. Additionally, the company's strategic review of the U.K. segment provides a potential positive catalyst in the near-term, said Tanquilut, who has a Buy rating and $40 price target on Acadia shares.
07/31/19
RAJA
07/31/19
DOWNGRADE
Target $45
RAJA
Outperform
Acadia downgraded to Outperform from Strong Buy at Raymond James
Raymond James analyst John Ransom downgraded Acadia Healthcare to Outperform from Strong Buy with a $45 price target. The analyst sees risk to Q3 estimates and ongoing uncertainty in the U.K. following the company's Q2 results.
09/03/19
EVER
09/03/19
NO CHANGE
EVER
Evercore says Tenet has highest exposure among hospitals to Dorian's new path
Evercore ISI analyst Michael Newshel estimates that Tenet (THC) has 22% of its beds in coastal counties in Florida, Georgia, South Carolina and North Carolina, where mandatory evacuations have been ordered in certain coastal areas due to the expected path of Hurricane Dorian. HCA Healthcare (HCA) has 15% of its beds in coastal counties in Florida, George and South Carolina, including 8% in counties that have received evacuation orders, while Universal Health (UHS) has one acute hospital, representing 3.6% of its total acute beds, in the affected coastal counties, and 8% of its behavioral beds are in coastal counties, the analyst noted. Newshel said Community Health (CYH), Quorum Health (QHC) and Acadia (ACHC) do not have any coastal exposure in the four states expected to be most impacted by Dorian.
ALNA Allena Pharmaceuticals
$4.12

-0.15 (-3.51%)

08/05/19
FBCO
08/05/19
INITIATION
Target $26
FBCO
Outperform
Allena Pharmaceuticals assumed with an Outperform at Credit Suisse
Credit Suisse analyst Martin Auster assumed coverage of Allena Pharmaceuticals with an Outperform rating and $26 price target.
01/18/19
BARD
01/18/19
INITIATION
Target $20
BARD
Outperform
Allena Pharmaceuticals initiated with an Outperform at Baird
Baird initiated Allena Pharmaceuticals with an Outperform and $20 price target.
07/10/19
FBCO
07/10/19
INITIATION
Target $26
FBCO
Outperform
Allena Pharmaceuticals assumed with an Outperform at Credit Suisse
Credit Suisse analyst Uy Ear assumed coverage of Allena Pharmaceuticals with an Outperform rating and $26 price target.
08/08/19
ROTH
08/08/19
NO CHANGE
Target $31
ROTH
Buy
Allena Pharmaceuticals price target lowered to $31 from $61 at Roth Capital
Roth Capital analyst Yasmeen Rahimi lowered her price target for Allena Pharmaceuticals to $31 from $61 driven by reduction in reloxaliase annual cost from $55k to $45k amid a more price sensitive macro-environment. The analyst notes that the company gave its Q2 update, which was "plain vanilla," with topline readout for URIROX-1 remaining on track for the second half of 2019. Rahimi reiterates a Buy rating on the shares.
APLS Apellis
$28.50

1.1 (4.01%)

07/12/19
JPMS
07/12/19
UPGRADE
Target $49
JPMS
Overweight
Apellis upgraded to Overweight with $49 price target at JPMorgan
JPMorgan analyst Anupam Rama upgraded Apellis Pharmaceuticals to Overweight from Neutral and raised his price target for the shares to $49 from $35.The analyst continues to believe APL-2 is an underappreciated asset in the complement space, with opportunities that span geographic atrophy and paroxysmal nocturnal hemoglobinuria in the later stage. Investor focus in the near term will be on the upcoming phase 3 PEGASUS readout of APL-2 in PNH anticipated in December, Rama tells investors in a research note. Early data with APL-2 suggests a potential differentiated option in the disease with respect to hemoglobin increase and other hematological indicators, he adds.
07/08/19
OPCO
07/08/19
INITIATION
Target $52
OPCO
Outperform
Apellis initiated with an Outperform at Oppenheimer
Oppenheimer analyst Justin Kim initiated Apellis with an Outperform rating and $52 price target.
07/09/19
07/09/19
INITIATION
Target $52

Outperform
Oppenheimer bullish on Apellis, initiates with an Outperform
As previously reported, Oppenheimer analyst Justin Kim started coverage of Apellis with an Outperform rating and $52 price target. The analyst believes its lead asset APL-2 is well positioned to address the high unmet need in geographic atrophy where no treatment options currently exist, while also addressing deeper unmet need in a defined orphan blood disorder. With the Phase 3 PNH study fully enrolled and Phase 3 studies in GA enrolling this year, Kim anticipates the shares could re-rate favorably over the coming 12-18 months.
07/12/19
JPMS
07/12/19
UPGRADE
Target $49
JPMS
Overweight
Apellis upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded Apellis Pharmaceuticals to Overweight from Neutral and raised his price target for the shares to $49 from $35.
ARWR Arrowhead
$34.25

1.02 (3.07%)

07/18/19
PIPR
07/18/19
NO CHANGE
Target $10
PIPR
Overweight
Spring Bank research agreement with NIAID 'smart,' says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes that Spring Bank (SBPH) entered into a research agreement with the National Institute of Allergy and Infectious Diseases, or NIAID, to study preclinical HBV antisense oligonucleotides. With the recent Arrowhead (ARWR) partnership with Janssen (JNJ), the analyst sees this as a "smart development program" building on Spring Bank's HBV expertise. Tenthoff also notes that Spring Bank is conducting the Phase IIb CATALYST 1 and 2 trials of 400mg inarigivir monotherapy/combination with Vemlidy in naive and suppressed HBV patients with preliminary data in the second quarter of 2020, while partner Gilead (GILD) is conducting a Phase II study of inarigivir plus Vemlidy in naive and suppressed HBV patients with initial data likely at AASLD in November. He reiterates an Overweight rating and $10 price target on Spring Bank's shares.
06/28/19
06/28/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. 1. Walgreens Boots Alliance (WBA) downgraded to Neutral from Outperform at Credit Suisse with analyst A.J. Rice saying Walgreens cut its guidance for FY19 and reduced its long-term EPS growth target to the mid-to-high single digits and said he would want to see clear indications that visibility on earnings growth is improving before considering raising his rating. 2. Biogen (BIIB) downgraded to Neutral from Overweight at Piper Jaffray with analyst Christopher Raymond saying Piper's new neurologist survey data from Spherix Global Insights "spells bad news for both Tecfidera and Tysabri in the near and longer term." 3. Live Nation (LYV) downgraded to Sell from Neutral at Citi with analyst Jason Bazinet saying he still likes the company's growth prospects and "consistent" operating performance. 4. Arrowhead (ARWR) downgraded to Neutral from Overweight at Cantor Fitzgerald with analyst Elemer Piros saying he views the stock as fairly valued. 5. Darden (DRI) downgraded to Equal Weight from Overweight at Stephens with analyst Will Slabaugh citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/28/19
CANT
06/28/19
DOWNGRADE
Target $24
CANT
Neutral
Arrowhead downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros last night downgraded Arrowhead Pharmaceuticals to Neutral from Overweight with an unchanged price target of $24. Following the 1,700% rally over the past two years, the analyst views the stock as fairly valued.
08/06/19
PIPR
08/06/19
NO CHANGE
Target $50
PIPR
Overweight
Arrowhead price target raised to $50 from $33 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals to $50 from $33 and reiterates an Overweight rating on the shares following the company's fiscal Q3 results. Arrowhead ended the quarter with cash of $295M and could soon receive a $25M milestone from Janssen for initiating Phase II REEF-1 study of JNJ-3989, Tenthoff tells investors in a research note. The analyst sees the cash position advancing Arrowhead's wholly-owned TRiM pipeline.
BPMC Blueprint Medicines
$75.35

1.34 (1.81%)

08/15/19
RAJA
08/15/19
INITIATION
RAJA
Market Perform
Blueprint Medicines resumed with a Market Perform at Raymond James
Raymond James analyst Dana Leone resumed coverage of Blueprint Medicines with a Market Perform rating saying he would like to see more clarity regarding clinical datasets within the RET+ lung and thyroid studies.
08/29/19
PIPR
08/29/19
INITIATION
Target $85
PIPR
Neutral
Blueprint Medicines initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Christopher Raymond started Blueprint Medicines (BPMC) with a Neutral rating and $85 price target. The analyst, while impressed with the company's "well demonstrated developmental track record and platform capability," sees a full valuation at current share levels. Further, the competitive disadvantage for Blueprint's lead asset avapritinib relative to Deciphera's (DCPH) ripretinib is not completely understood, Raymond tells investors in a research note.
08/20/19
PIPR
08/20/19
NO CHANGE
Target $55
PIPR
Overweight
Deciphera still offers 'significant upside', says Piper Jaffray
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $55 price target on Deciphera (DCPH), anticipating several catalysts over the next few quarters to play out. The analyst cites continued upside from ripretinib's profile in earlier lines of GIST to continue to emerge and also believes the stock can benefit from an increasingly flattering comp from its competitor Blueprint Medicines' (BPMC) avapritinib, particularly as the toxicity of that agent becomes more apparent.
08/13/19
08/13/19
NO CHANGE
Target $68

Buy
Deciphera INVICTUS results best-case scenario, price target raised at Guggenheim
As previously reported, Guggenheim analyst Michael Schmidt raised his price target for Deciphera (DCPH) to $66 from $44 after the company announced top-line results from the Phase 3 INVICTUS study of ripretinib in 4L+ GIST, which he believes "significantly exceeded" investors' expectations and validated his bullish thesis and analyses heading into the binary event. The analyst notes that results included a 6.3 months mPFS readout in a setting with no approved therapies and also compare favorably to competitor data from Blueprint Medicines (BPMC) in similar patients. Together with updated Phase 1 ripretinib data across 2L and 3L GISTs, Schmidt thinks these results read-through positively also for the drug's potential in earlier stage GIST patients. Deciphera's Phase 3 INTRIGUE trial in 2L GIST will complete enrolling in the second quarter of 2020, he adds. The analyst has a Buy rating on Deciphera's shares.
CERS Cerus
$5.03

-0.24 (-4.55%)

01/28/19
CANT
01/28/19
NO CHANGE
Target $9
CANT
Overweight
Cantor sees catalysts for upside to Cerus sales growth estimates
Cantor Fitzgerald analyst Craig Bijou reiterates an Overweight rating on Cerus with a $9 price target after hosting meetings with management. The analyst came away "encouraged that the cadence of catalysts over the next several years" could drive upside to his current estimates. Bijou expects pathogen-reduced platelet penetration, led by accelerating American Red Cross adoption, to be the company's primary driver of sales growth in 2019. Faster U.S. platelet penetration and other near-term catalysts should drive upside to revenue growth estimates in 2019 and beyond, the analyst tells investors in a research note. He also believes finalization of FDA guidance, expected in 2019, should accelerate the adoption of U.S. pathogen-reduced platelets.
08/28/19
08/28/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cerus (CERS) initiated with a Buy at Stifel. 2. DouYu (DOYU) initiated with an Overweight at JPMorgan. 3. Myovant Sciences (MYOV) initiated with a Buy at Goldman Sachs. 4. Anaplan (PLAN) initiated with an Outperform at RBC Capital. 5. Alphatec (ATEC) initiated with a Buy at Canaccord. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/22/19
SPHN
08/22/19
INITIATION
Target $8
SPHN
Overweight
Cerus resumed with an Overweight at Stephens
Stephens analyst Jacob Johnson resumed coverage of Cerus with an Overweight rating and a price target of $8. The analyst says the company's pathogen reduction technology is increasingly recognized as a "vital tool" in blood safety, and he sees "numerous" catalysts on the horizon, including the final "key" guidance from the FDA on platelets next month. Johnson further cites additional potential catalysts expected in 2020 and beyond, including international opportunity for platelets along with pathogen-reduced cryoprecipitate approval in the U.S.
08/27/19
STFL
08/27/19
INITIATION
Target $7
STFL
Buy
Cerus initiated with a Buy at Stifel
Stifel analyst Mathew Blackman started Cerus with a Buy rating and $7 price target. The analyst sees "significant potential upside" over time as the company executes against "high-value" commercial and pipeline opportunities that he believes are not yet adequately reflected in the valuation. Cerus's blood pathogen-reduction technology has demonstrated commercial momentum over the past 12 months, and the company's billion-dollar-plus addressable market opportunities are only "marginally appreciated," Blackman tells investors in a research note.
EHC Encompass Health
$60.25

-0.58 (-0.95%)

08/12/19
CHLM
08/12/19
NO CHANGE
Target $76
CHLM
Buy
Encompass Health price target lowered to $76 from $81 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich lowered his price target for Encompass Health to $76 from $81 as he believes the company's outlook for Medicare's reimbursement change to the PatientDriven Groupings Model and the proposed 8.01% reduction to the base rate associated with behavioral assumptions is a worst-case scenario and could prove conservative due to proposed legislation. The analyst reiterates a Buy rating on the shares.
08/05/19
JEFF
08/05/19
NO CHANGE
Target $80
JEFF
Buy
Encompass Health share selloff 'disconnected' from results, says Jefferies
The post-earnings pullback in shares of Encompass Health is "disconnected from the strong results" and management's "conservative" guidance raise that should lead to EBITDA upside in the second half of 2019, Jefferies analyst Brian Tanquilut tells investors in a research note. The analyst, who recognizes concerns over the company's 2020 earnings power given management's comments about upcoming headwinds, reiterates a Buy rating on Encompass with an $80 price target.
07/31/19
PIPR
07/31/19
NO CHANGE
Target $77
PIPR
Overweight
Encompass Health selloff yesterday a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Sarah James lowered her price target for Encompass Health to $77 from $92 but views yesterday's share selloff as a buying opportunity. While sentiment is driven heavily by rates, the larger impact on the earnings potential is growth in the stroke market and effective capital deployment, James tells investors in a post-earnings research note. She believes Encompass is likely to gain share from smaller companies and keeps an Overweight rating on the name.
07/12/19
WBLR
07/12/19
NO CHANGE
WBLR
William Blair stays Outperform on Healthcare Delivery names after CMS proposal
The fiscal 2020 Medicare payment and policy proposal for home health agencies was published last night, William Blair analyst Matt Larew tells investors in a research note. He points out that the proposal includes an update on the shift to the "Patient-Driven Groupings Model,"and moves the unit of payment from a 60-day period to a 30-day period. As expected, the language related to the proposed "behavioral adjustment" remained in the proposal, Larew says. The cumulative rate cut that Centers for Medicare and Medicaid Services forecasts to offset assumed behavioral changes increased from 6.42% to 8.01%, largely to account for the number of clinical coding groups moving from six to 12 groups, he notes. However, the estimated 30-day payment after incorporating the behavioral assumptions actually increased slightly from $1,753.68 to $1,754.37, according to the analyst. Larew did not expect the behavioral cuts to be removed in the proposal and believes the "Patient-Driven Groupings Model" itself will prove manageable for large Healthcare Delivery players like Amedisys (AMED), Encompass Health (EHC), and LHC Group (LHCG). The analyst has Outperform ratings on all three. The changes in the rate/dollar calculations were a bit surprising, but the "dollars" are more important than the "rates" and the dollars were unchanged, contends Larew.
EIGR Eiger BioPharmaceuticals
$10.60

-0.27 (-2.48%)

04/24/19
WEDB
04/24/19
NO CHANGE
Target $35
WEDB
Outperform
Eiger BioPharmaceuticals price target lowered to $35 from $43 at Wedbush
Wedbush analyst Liana Moussatos lowered her price target for Eiger BioPharmaceuticals to $35 from $43 due to financing share dilution. The analyst notes that Eiger recently announced pricing of a follow-on offering to raise approximately $49.50M. Moussatos estimates net proceeds of $44.55M and project cash runway into Q1 of 2021, which covers important clinical, regulatory and commercial activities. She reiterates an Outperform rating on the shares.
06/26/19
SBSH
06/26/19
INITIATION
Target $22
SBSH
Buy
Eiger BioPharmaceuticals initiated with a Buy at Citi
Citi analyst Yigal Nochomovitz initiated Eiger BioPharmaceuticals with a Buy rating and $22 price target, noting that he assumes 60% odds of success for lonafarnib and 50% odds of success for pegylated interferon, both of which the company is developing to treat hepatitis D. Eiger is also developing lonafarnib for progeria, a fatal rare disease marked by premature aging, noted Nochomovitz, who assumes a 90% chance of success in that indication.
01/29/19
01/29/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Dell Technologies (DELL) initiated with an Outperform at Raymond James. 2. MasterCard (MA) and Visa (V) were initiated with a Buy at Jefferies. 3. Eiger BioPharmaceuticals (EIGR) initiated with an Outperform at Baird. 4. Arena Pharmaceuticals (ARNA) assumed with an Overweight at Cantor Fitzgerald. 5. Southern Copper (SCCO) reinstated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/18/19
JEFF
06/18/19
NO CHANGE
Target $27
JEFF
Buy
Eiger breakthrough designation a surprise, says Jefferies
Jefferies analyst Maury Raycroft says the Breakthrough Therapy Designation for Eiger BioPharmaceuticals' avexatide in post-bariatric hypoglycemia came as a surprise. The company's PBH program is more under-the-radar for investors, given its focus on hepatitis delta virus and the near-term new drug application filing for Progeria syndrome and Progeroid Laminopathies, Raycroft tells investors in a res research note. He views last night's news as a positive and keeps a Buy rating on Eiger BioPharmaceuticals with a $27 price target.
GNCA Genocea
$3.46

0.24 (7.45%)

02/28/19
HCWC
02/28/19
NO CHANGE
Target $5.75
HCWC
Buy
Genocea price target raised on higher GEN-009 odds of success at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated his Buy rating on Genocea Biosciences and raised his price target to $5.75 from $5.00 after increasing his projected chance of success for GEN-009 to 15% from 10% based on the "increasingly strong profile" of the ATLAS platform, as demonstrated most recently at SITC 2018. He also adjusted the share count to account for a recent equity raise and projected impacted from a second tranche of this raise. Pantginis keeps a Buy rating on Genocea.
07/08/19
STFL
07/08/19
INITIATION
Target $13
STFL
Buy
Genocea resumed with a Buy at Stifel
Stifel analyst Benjamin Burnett resumed coverage of Genocea with a Buy rating and $13 price target after the firm was a joint book running manager for the company's 10M shares secondary offering of common stock. He thinks investors have underappreciated the "compelling" immunogenicity phase 1 data from GEN-009, Genocea's lead program, Burnett tells investors. Genocea's current valuation, which is at the low range of peers, makes the shares worth owning ahead of clinical efficacy data expected in 2020, Burnett contends.
07/25/19
HCWC
07/25/19
NO CHANGE
Target $32
HCWC
Buy
Genocea price target lowered to $32 from $42 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered his price target on Genocea shares to $32 from $42 to reflect the recent dilution from the company's equity raise, but he keeps a Buy rating on the stock as he believes the company has "set an exciting agenda for the remaining of the year." Genocea showed "encouraging data" on the company's neoantigen platform ATLAS at both the SITC meeting in November 2018 and at AACR in March 2019, Pantginis said.
06/03/19
HCWC
06/03/19
NO CHANGE
Target $42
HCWC
Buy
Genocea price target raised to $42 from $5.75 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Genocea Biosciences to $42 from $5.75 after the company present immunological data from the ongoing Phase 1/2a study with GEN-009. With these data, "ATLAS is now squarely thrust into the neoantigen fray with potentially superior data compared to comps that use algorithm approaches," Pantginis tells investors in a research note. He keeps a Buy rating on shares of Genocea.
HARP Harpoon Therapeutics
$14.50

0.2 (1.40%)

04/22/19
BARD
04/22/19
INITIATION
Target $25
BARD
Outperform
Harpoon Therapeutics initiated with an Outperform at Baird
Baird analyst Michael Ulz started Harpoon Therapeutics with an Outperform rating and $25 price target.
03/05/19
ADAM
03/05/19
INITIATION
Target $24
ADAM
Buy
Harpoon Therapeutics initiated with a Buy at Canaccord
Canaccord initiated Harpoon Therapeutics with a Buy and $24 price target.
03/05/19
ADAM
03/05/19
INITIATION
Target $24
ADAM
Buy
Harpoon Therapeutics initiated with a Buy at Canaccord
Canaccord analyst Arlinda Lee initiated Harpoon Therapeutics with a Buy as she sees solid prospects for it lead drug candidate TriTac, which engages T cells to harness the body's immune system to treat cancer and other diseases. Lee has a $24 price target on Harpoon Therapeutics shares.
05/24/19
SBSH
05/24/19
INITIATION
Target $23
SBSH
Buy
Harpoon Therapeutics assumed with a Buy at Citi
Citi analyst Yigal Nochomovitz assumed coverage of Harpoon Therapeutics with a Buy rating and lowered his price target for the shares to $23 from $25. The analyst sees potential for upside over the next 12 months from initial clinical data from lead drug HPN424 in prostate cancer and HPN536 in mesothelin positive cancers.
HNGR Hanger
$18.69

0.05 (0.27%)

RARE Ultragenyx
$45.00

-6.28 (-12.25%)

08/02/19
08/02/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL), Facebook (FB), and Amazon.com (AMZN) initiated with a Buy at MKM Partners. 2. iHeartMedia (IHRT) initiated with an Overweight at JPMorgan. 3. NuStar Energy (NS) initiated with a Neutral at Mizuho. 4. Ultragenyx (RARE) assumed with an Outperform at Wedbush. 5. Avantor (AVTR) initiated with a Neutral at Cleveland Research. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/04/19
PIPR
09/04/19
NO CHANGE
Target $75
PIPR
Overweight
Ultragenyx announced positive DTX401 update, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on shares of Ultragenyx Pharmaceutical with a $75 price target following today's DTX401 update. All three patients in cohort 2 saw increases in time to hypoglycemia, with additional reductions in cornstarch consumption and daily cornstarch intake continuing to be tapered, Raymond tells investors in a research note. The analyst says that while DTX401 represents just $6 per share in his sum-of-the-parts analysis, he thinks this success should draw more attention to Ultragenyx's broader gene therapy effort, which he believes is underappreciated.
09/04/19
LEER
09/04/19
NO CHANGE
Target $85
LEER
Outperform
Ultragenyx price target raised to $85 from $80 at SVB Leerink
SVB Leerink analyst Joseph Schwartz raised his price target for Ultragenyx to $85 from $80 as he remains positive on DTX401 on the heels of encouraging Phase 1/2 cohort 2 data. The analyst notes that cohort 2 update is encouraging although the benefits reported may be more modest since the data could be confounded by the influence of cornstarch. Although the stock is down likely due to the company pushing out its Phase 1/2 cohort 3 update for DTX301 to Q4, potentially enrolling a more diverse patients group for its Phase 1/2 dose confirmation study for DTX401 and uncertainty on Phase 3 endpoints for DTX401, Schwartz remains positive on DTX401 as he believes that Ultragenyx could continue to deliver clinical benefit for patients. He reiterates an Outperform rating on the shares.
08/15/19
08/15/19
NO CHANGE

JMP Securities says Ultragenyx partnership with GeneTx a positive
JMP Securities analyst Liisa Bayko maintained an Outperform rating and $82 price target on Ultragenyx (RARE), after the company announced a partnership with GeneTx to develop preclinical asset GTX-102, which is for the treatment of Angelman Syndrome. The analyst liked the partnership, noting that it "extends the company's rare disease focus from small molecules and therapeutic proteins to oligonucleotide therapies," which the analyst believes is a significant growth area.
PODD Insulet
$157.27

-10.29 (-6.14%)

08/06/19
JEFF
08/06/19
NO CHANGE
Target $140
JEFF
Buy
Insulet price target raised to $140 from $105 at Jefferies
Jefferies analyst Raj Denhoy raised his price target for Insulet to $140 from $105 saying Omnipod adoption "remains hot" following the company's better than expected Q2 results. The launch of Dash, the accompanying move to pharmacy benefit, and the general adoption of technology broadly in diabetes continue to spur growth, Denhoy tells investors in a research note. The analyst raised his estimates and keeps a Buy rating on Insulet.
08/06/19
BMOC
08/06/19
NO CHANGE
Target $150
BMOC
Outperform
Insulet price target raised to $150 from $130 at BMO Capital
BMO Capital analyst Joanne Wuensch raised her price target on Insulet to $150 and kept her Outperform rating after its Q2 results and above-consensus Q3 guidance, saying the company continues a streak of beat-and-raise quarters among diabetes management companies. The analyst further cites Insulet's 4th consecutive quarter of revenue growth over 20% and points to its Horizon artificial pancreas system coming online by the end of 2020, with added benefits coming from the company's international direct sales efforts.
08/06/19
RAJA
08/06/19
NO CHANGE
Target $135
RAJA
Outperform
Insulet price target raised to $135 from $125 at Raymond James
Raymond James analyst Jayson Bedford raised his price target for Insulet to $135 from $125 and maintained an Outperform rating, saying the company generated significant momentum in the second quarter and the revenue beat was the company's largest in over two years. In a research note to investors, Bedford says it is "tough to poke holes" in Q2, and says the raised guidance implies continued momentum. The analyst notes that Horizon, and possibly Tidepool, launching in late 2020 provides visibility into additional growth drivers, giving him confidence in the sustainability of the underlying growth profile.
08/06/19
BTIG
08/06/19
NO CHANGE
Target $140
BTIG
Buy
Insulet price target raised to $140 from $130 at BTIG
BTIG analyst Sean Lavin raised his price target on Insulet to $140 and kept his Buy rating after its Q2 results and above-consensus Q3 guidance, saying the company is benefiting from "strong drivers" and the growing demand for diabetes technology, including both CGMs and insulin pumps. The analyst further cites Insulet's release of its new DASH platform and its "no-commitment" adoption model along with expanded payor coverage and its move toward the pharmacy channel combining to improve the ease of access to its technology for patients and payors.
PIRS Pieris Pharmaceuticals
$4.99

0.15 (3.10%)

07/29/19
WBLR
07/29/19
NO CHANGE
WBLR
Outperform
Updates 'very positive' for upcoming Pieris presentation, says William Blair
Pieris Pharmaceuticals (PIRS) will present Phase Ib safety and efficacy results with PRS-060, an inhaled IL-4R alpha inhibitor, at the upcoming European Respiratory Society International Congress, held September 28 through October 2, William Blair analyst Matt Phipps tells investors in a research note. The poster presentation to be presented on October 1 is titled, "Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma," the analyst point out. In addition, AstraZeneca (AZN) plans to initiate a Phase II trial with AZD1402/PRS-060 in the second half of this year, according to its recent earnings presentation, adds Phipps. He views these updates as "very positive" for the upcoming presentation, and believes PRS-060 has "significant potential" in the treatment of asthma patients. Phipps keeps an Outperform rating on Pieris Pharmaceuticals.
05/14/19
BARD
05/14/19
INITIATION
Target $5
BARD
Outperform
Pieris Pharmaceuticals initiated with an Outperform at Baird
Baird analyst Madhu Kumar initiated Pieris Pharmaceuticals with an Outperform rating and $5 price target, saying he believe's Pieris' anticalin platform has the potential to disrupt biologic therapies in the respiratory and oncology spaces. The analyst called out the company's Phase 1 single ascending dose results for anti-interleukin-4 receptor a Ac PRS060 as potentially validating the drug's utility in asthma and serve as a positive catalyst for shares.
05/13/19
BARD
05/13/19
INITIATION
Target $5
BARD
Outperform
Pieris Pharmaceuticals initiated with an Outperform at Baird
Baird analyst Madhu Kumar initiated Pieris Pharmaceuticals with an Outperform and $5 price target.
07/30/19
BARD
07/30/19
DOWNGRADE
Target $5
BARD
Neutral
Pieris Pharmaceuticals downgraded to Neutral from Outperform at Baird
Baird analyst Madhu Kumar downgraded Pieris Pharmaceuticals to Neutral from Outperform with an unchanged price target of $5.
NVCR Novocure
$84.39

-2.82 (-3.23%)

07/26/19
WEDB
07/26/19
DOWNGRADE
Target $80
WEDB
Neutral
Novocure downgraded to Neutral from Outperform at Wedbush
Wedbush analyst David Nierengarten downgraded Novocure to Neutral from Outperform, telling he believes shares are now fully valued at the current levels following its recent performance. The analyst raised his price target to $80 from $57 to reflect current positive glioblastoma adoption trends, and notes that longer-term, positive results from clinical trials in new indications could give revenues a new growth trajectory beyond the underlying core GBM franchise. Nierengarten advises investors to wait for a more attractive entry point, as risks outweigh the rewards at these levels.
07/26/19
WEDB
07/26/19
DOWNGRADE
WEDB
Neutral
Novocure downgraded to Neutral from Outperform at Wedbush
07/29/19
RHCO
07/29/19
UPGRADE
Target $105
RHCO
Buy
Novocure upgraded to Buy from Hold at SunTrust
SunTrust analyst Gregory Gilbert upgraded Novocure to Buy from Hold and raised his price target for the shares to $105 from $48.
07/29/19
07/29/19
UPGRADE
Target $105

Buy
Novocure upgraded to Buy from Hold at SunTrust
As previously reported, SunTrust analyst Gregory Gilbert upgraded Novocure to Buy from Hold and raised his price target for the shares to $105 from $48. The analyst says that he has long recognized the stock as an "under-the-radar" oncology investment story that calls for investor attention, but notes that the interest and excitement about Optune's potential in future indications is growing. Gilbert notes that his updated model now includes "probability adjusted" sales for Phase 3 indications with some areas of "potential conservatism".
NBIX Neurocrine
$97.70

-0.31 (-0.32%)

08/07/19
08/07/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Bilibili (BILI) initiated with a Buy at Goldman Sachs. 2. Waste Connections (WCN) was initiated with an Overweight at JPMorgan, while Waste Management (WM) and Republic Services (RSG) were initiated with a Neutral. 3. Neurocrine (NBIX) initiated with an Outperform at RBC Capital. 4. Brookfield Property (BPY) initiated with an Outperformer at CIBC. 5. Dropbox (DBX) initiated with an Underperform at Bernstein. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/30/19
FBCO
07/30/19
NO CHANGE
Target $110
FBCO
Outperform
Neurocrine price target raised to $110 from $95 at Credit Suisse
Credit Suisse analyst Evan Seigerman raised his price target for Neurocrine to $110 from $95 and raised Ingrezza sales to $200M in Q3 following the "solid" quarterly beat. The analyst believes that Ingrezza has much more room to grow, and that the company's expanded promotional efforts are likely to drive continued penetration into the addressable TD market which he estimates to be over 500k patients in the U.S. Seigerman reiterates an Outperform rating on the shares.
08/28/19
GSCO
08/28/19
NO CHANGE
Target $110
GSCO
Buy
Slower Orilissa ramp has minimal impact on Neurocrine, says Goldman Sachs
To reflect the slower than expected ramp in sales of Orilissa in endometriosis, Goldman Sachs analyst Paul Choi lowered his Neurocrine Biosciences (NBIX) forecasts of Orilissa royalties. He projects similar 40% market share by 2026 for both Myovant Sciences' (MYOV) relugolix and Orilissa within endometriosis and uterine fibroid patients treated with a GnRH receptor antagonists. However, in the near-term, since Orilissa royalties are a small fraction of Neurocrine's revenue, these changes have little impact on the company's top- and bottom- lines, says Choi. As such, the analyst keeps a Buy rating on Neurocrine Biosciences with a $110 price target.
08/07/19
RBCM
08/07/19
INITIATION
Target $118
RBCM
Outperform
Neurocrine initiated with an Outperform at RBC Capital
RBC Capital analyst Brian Abrahams initiated Neurocrine with an Outperform rating and a price target of $118, saying the company's "high-growth, low-risk" profile should "continue to stand out." The analyst is positive on Neurocrine's strong near-term Ingrezza growth based on his market analysis, current trends, and physician feedback. Abrahams also believes the company has the potential for pipeline candidates to drive incremental longer-term revenue growth and sees that opportunity as "underappreciated" in the market.
MYOV Myovant Sciences
$8.20

0.07 (0.86%)

08/28/19
GSCO
08/28/19
INITIATION
Target $20
GSCO
Buy
Myovant Sciences initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Paul Choi started Myovant Sciences with a Buy rating and $20 price target. The "overreaction" on data concerns provides a good entry point into a stock with "attractive" pipeline optionality, Choi tells investors in a research note. The investor debate over the intermediate term will center on the market opportunity for the GnRH antagonist class and what share relugolix can attain, contends the analyst. Choi, however, thinks that the market has excessively discounted Myovant's prospects as his key opinion leader checks indicate no concerns about relugolix's placebo-adjusted response rate and enthusiasm for another treatment option for endometriosis and uterine fibroid.
08/19/19
08/19/19
INITIATION
Target $26

Outperform
SVB Leerink bullish on Myovant Sciences, initiates with an Outperform
As previously reported, SVB Leerink analyst Ami Fadia started coverage of Myovant Sciences with an Outperform and a $26 price target. The analyst notes that Myovant's lead product relugolix is poised to become the second gonadotropin releasing hormone antagonist for treating endometriosis and uterine fibroids, and maintains her positive outlook on the GnRH antagonists market, which she believes could grow to over $4.5B in sales in 2025 and support multiple products. While Fadia acknowledges that expectations for Myovant have been reset following the recent relugolix Phase 3 data in UF, which may have been disappointing relative to expectations for a best-in-class profile, at current levels she believes the market underestimates relugolix's $1B sales potential in 2025 based on its tolerability profile and convenient dosing regimen.

TODAY'S FREE FLY STORIES

UPS

UPS

$120.71

1.61 (1.35%)

21:22
09/20/19
09/20
21:22
09/20/19
21:22
Conference/Events
UPS management to meet with UBS »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

DIS

Disney

$132.18

-1.14 (-0.86%)

, T

AT&T

$37.92

0.78 (2.10%)

18:17
09/20/19
09/20
18:17
09/20/19
18:17
Periodicals
Disney reaches TV carriage agreement with AT&T, Bloomberg says »

The deal includes ESPN on…

DIS

Disney

$132.18

-1.14 (-0.86%)

T

AT&T

$37.92

0.78 (2.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

BA

Boeing

$379.33

-5.28 (-1.37%)

18:15
09/20/19
09/20
18:15
09/20/19
18:15
Periodicals
Icelandair reaches deal for Boeing to cover costs associated with 737, WSJ says »

Icelandair Group said it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

MCF

Contango Oil & Gas

$1.71

-0.07 (-3.93%)

17:58
09/20/19
09/20
17:58
09/20/19
17:58
Hot Stocks
Karlin Asset Management reports 11.4% passive stake in Contango Oil & Gas »

Karlin Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Shares

$142.97

1.68 (1.19%)

17:41
09/20/19
09/20
17:41
09/20/19
17:41
Hot Stocks
SPDR Gold Shares holdings rise to 894.15MT from 883.60MT »

This is the highest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VXRT

Vaxart

$0.58

-0.0307 (-5.03%)

17:37
09/20/19
09/20
17:37
09/20/19
17:37
Syndicate
Vaxart files to sell 15.6M shares of common stock »

H.C. Wainwright acted as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$217.69

-3.22 (-1.46%)

17:34
09/20/19
09/20
17:34
09/20/19
17:34
Periodicals
Apple given tariff exclusion on certain Mac Pro parts, Bloomberg says »

Apple has received U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IIVI

II-VI

$39.05

-0.5 (-1.26%)

, CPE

Callon Petroleum

$4.53

-0.015 (-0.33%)

17:31
09/20/19
09/20
17:31
09/20/19
17:31
Hot Stocks
II-VI to enter S&P 400; Callon Petroleum, PriceSmart to enter S&P SmallCap600 »

S&P SmallCap 600…

IIVI

II-VI

$39.05

-0.5 (-1.26%)

CPE

Callon Petroleum

$4.53

-0.015 (-0.33%)

PSMT

PriceSmart

$60.29

-0.39 (-0.64%)

FNSR

Finisar

$24.31

1.25 (5.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 02

    Oct

  • 30

    Oct

NVR

NVR

$3,632.55

-30.45 (-0.83%)

, JEF

Jefferies Financial Group

$19.47

-0.19 (-0.97%)

17:26
09/20/19
09/20
17:26
09/20/19
17:26
Hot Stocks
NVR to replace Jefferies Financial Group in the S&P 500 at open on September 26 »

NVR (NVR) will replace…

NVR

NVR

$3,632.55

-30.45 (-0.83%)

JEF

Jefferies Financial Group

$19.47

-0.19 (-0.97%)

SPB

Spectrum Brands

$49.66

-1.395 (-2.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

NOC

Northrop Grumman

$368.25

-7.45 (-1.98%)

17:24
09/20/19
09/20
17:24
09/20/19
17:24
Hot Stocks
Northrop Grumman subsidiary awarded $1.12B Missile Defense Agency contract »

Orbital Sciences, or OSC,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSMT

PriceSmart

$60.29

-0.39 (-0.64%)

, FNSR

Finisar

$24.31

1.25 (5.42%)

17:23
09/20/19
09/20
17:23
09/20/19
17:23
Hot Stocks
Breaking Hot Stocks news story on PriceSmart, Finisar »

PriceSmart to replace…

PSMT

PriceSmart

$60.29

-0.39 (-0.64%)

FNSR

Finisar

$24.31

1.25 (5.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

IIVI

II-VI

$39.05

-0.5 (-1.26%)

, CPE

Callon Petroleum

$4.53

-0.015 (-0.33%)

17:22
09/20/19
09/20
17:22
09/20/19
17:22
Hot Stocks
Breaking Hot Stocks news story on II-VI, Callon Petroleum »

II-VI to replace Callon…

IIVI

II-VI

$39.05

-0.5 (-1.26%)

CPE

Callon Petroleum

$4.53

-0.015 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 02

    Oct

NVR

NVR

$3,632.55

-30.45 (-0.83%)

17:20
09/20/19
09/20
17:20
09/20/19
17:20
Hot Stocks
Breaking Hot Stocks news story on NVR »

NVR to replace Jefferies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NHYDY

Norsk Hydro

$0.00

(0.00%)

17:12
09/20/19
09/20
17:12
09/20/19
17:12
Hot Stocks
Norsk Hydro discloses federal court in Brazil lifts embargo on Alunortes »

The Federal Court in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RESN

Resonant

$3.05

0.02 (0.66%)

17:03
09/20/19
09/20
17:03
09/20/19
17:03
Conference/Events
Resonant participates in a conference call with Loop Capital »

Semiconductor Analysts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 12

    Nov

NINE

Nine Energy Services

$6.73

-0.33 (-4.67%)

17:02
09/20/19
09/20
17:02
09/20/19
17:02
Syndicate
Breaking Syndicate news story on Nine Energy Services »

Nine Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATOM

Atomera

$3.70

0.17 (4.82%)

17:00
09/20/19
09/20
17:00
09/20/19
17:00
Conference/Events
Atomera participates in a conference call with Loop Capital »

Semiconductor Analysts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPWR

Monolithic Power

$154.21

-2 (-1.28%)

16:50
09/20/19
09/20
16:50
09/20/19
16:50
Conference/Events
Monolithic Power participates in a conference call with Loop Capital »

Semiconductor Analysts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

AAPL

Apple

$217.69

-3.22 (-1.46%)

16:45
09/20/19
09/20
16:45
09/20/19
16:45
Periodicals
Breaking Periodicals news story on Apple »

Apple given tariff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDA

IDACORP

$111.26

0.93 (0.84%)

16:36
09/20/19
09/20
16:36
09/20/19
16:36
Hot Stocks
IDACORP raises quarterly dividend to 67c from 63c per share »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

MO

Altria Group

$40.80

0.69 (1.72%)

16:33
09/20/19
09/20
16:33
09/20/19
16:33
Hot Stocks
Altria Group recommends rejection of amended mini-tender by TRC »

Altria Group states it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$0.00

(0.00%)

, AL

Air Lease

$42.68

-0.615 (-1.42%)

16:32
09/20/19
09/20
16:32
09/20/19
16:32
Hot Stocks
Air Lease announces delivery of new A321-200neo to Air Astana »

Air Lease Corporation…

EADSY

Airbus

$0.00

(0.00%)

AL

Air Lease

$42.68

-0.615 (-1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

16:30
09/20/19
09/20
16:30
09/20/19
16:30
Options
Preliminary option volume of 23.5M today »

Preliminary option volume…

PSX

Phillips 66

$103.26

0.14 (0.14%)

16:28
09/20/19
09/20
16:28
09/20/19
16:28
Periodicals
Phillips 66 says Beaumont oil terminal ops still shut down, Reuters says »

Phillips 66 said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

POST

Post Holdings

$105.73

0.335 (0.32%)

16:24
09/20/19
09/20
16:24
09/20/19
16:24
Hot Stocks
Post files IPO for active nutrition unit BellRing Brands »

Post Holdings, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.